Optimizing treatment with clozapine

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 3, 1998, Pages 44-48

  Conley, Robert R ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RISPERIDONE; SERTINDOLE;

AGRANULOCYTOSIS; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG RESPONSE; HOSPITAL ADMISSION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SUICIDE; TACHYCARDIA; TREATMENT FAILURE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG ADMINISTRATION SCHEDULE; DRUG INFORMATION SERVICES; DRUG MONITORING; HUMANS; REGISTRIES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0031980134     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Kane JM. Treatment-resistant schizophrenic patients. J Clin Psychiatry 1996;57(suppl 9):35-40
2. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-1752
3. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
4. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997;23:663-674
5. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Schizophrenia. Am J Psychiatry 1997;154(4, suppl):1-62
6. Kane JM, chairperson. Choosing Among Old and New Antipsychotics [ACADEMIC HIGHLIGHTS]. J Clin Psychiatry 1996;57:427-438
7. Tamminga CA. The promise of new drugs for schizophrenia treatment. Can J Psychiatry 1997;42:265-273
8. Citrome L. New antipsychotic medications. What advantages do they offer? Postgrad Med J 1997;101:207-214
9. Mallya AR, Roos PD, Roebuck-Colgan K. Restraint, seclusion, and clozapine. J Clin Psychiatry 1992;53:395-397
10. Volavka J, Zito JM, Vitrai J, et al. Clozapine effects on hostility and aggression in schizophrenia [letter]. J Clin Psychopharmacol 1993;13:287-289
11. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997;8:671-677
12. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment in neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190
13. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55(9, suppl B):102-106
14. Van Harten PN, Kamphuis DJ, Matroos GE. Use of clozapine in tardive dystonia. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:263-274
15. Buckley P, Thompson PA, Way L, et al. Substance abuse and clozapine treatment. J Clin Psychiatry 1994;55(9, suppl B):114-116
16. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine [letter]. Am J Psychiatry 1995;152:959
17. Clozapine Study Group. The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. Br J Psychiatry 1993;163:150-154
18. Honigfeld G. The Clozapine National Registry System: forty years of risk management. J Clin Psychiatry Monograph 1996;14(2):29-32
19. Weiden PJ, Aquila R, Dalheim L, et al. Switching antipsychotic medications. J Clin Psychiatry 1997;58(suppl 10):63-72
20. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26
21. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992; 160(suppl 17):46-53
22. Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hospital and Community Psychiatry 1990;41:882-885
23. Jibson MD E, Tandon R. A summary of research findings on the new antipsychotic drugs. Essent Psychopharmacol 1996;1:27-37
24. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614
25. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58(suppl 10):55-62
26. Conley RR, Carpenter WT Jr, Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry 1997;154:1243-1247
27. VanderZwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996;153:1579-1584
28. Bloom FE. Advancing a neurodevelopmental origin for schizophrenia. Arch Gen Psychiatry 1993;50:224-227
29. Waddington JL. Neurodynamics of abnormalities in cerebral metabolism and structure in schizophrenia. Schizophr Bull 1993;19:55-69
30. Shore D, Matthews S, Cott J, et al. Clinical implications of clozapine discontinuation: report of an MMH workshop. Schizophr Bull 1995;21: 333-338
31. Gardos G, Cole JO, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 1978;135:1321-1324
32. Dilsaver SC. Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Saf 1994;10:103-114
33. Shiovitz TM, Welke TL, Tigel PD, et al. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 1996;22:591-595
34. Still DJ, Dorson PG, Crismon ML, et al. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996;47:1382-1384
35. Gupta S, Daniel DG. Cautions in the clozapine-to-risperidone switch [letter]. Ann Clin Psychiatry 1995;7:149
36. Parsa MA, Al-Lahham YH, Ramirez JF, et al. Prolonged psychotic relapse after abrupt clozapine withdrawal. J Clin Psychopharmacol 1993;13: 154-155
37. Kinon BJ, Kane JM, Johns C, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993;29:309-314
38. Stahl SM. Mental illness may be damaging to your brain [BRAINSTORMS]. J Clin Psychiatry 1997;58:289-290
39. Baldessarini RJ, Gardner DM, Garver DL. Conversions from clozapine to other antipsychotic drugs [letter]. Arch Gen Psychiatry 1995;52: 1071-1072
40. Simpson GM, Meyer JM. Dystonia while changing from clozapine to risperidone [letter]. J Clin Psychopharmacol 1996;16:260-261
41. Radford JM, Brown TM, Borison RL. Unexpected dystonia while changing from clozapine to risperidone [letter]. J Clin Psychopharmacol 1995; 15:225-226
42. Lacey RL, Preskom SH, Jerkovich GS. Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics? [letter]. Am J Psychiatry 1995;152:1401
43. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-429
44. Baker RW, Conley RR. Seizures in clozapine-treated patients [letter]. Am J Psychiatry 1991;148:1265-1266
45. Idänpään-Heikkilä J, Alhava E, Olkinuora M, et al. Clozapine and agranulocytosis. Lancet 1975;2:611
46. Atkin K, Kendall F, Gould D, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996;169: 483-488
47. Lamberti JS, Bellnier TJ, Schwarzkopf SB, et al. Filgrastim treatment of three patients with clozapine-induced agranulocytosis. J Clin Psychiatry 1995;56:256-259
48. Meltzer HY. Clozapine: is another view valid? [editorial] Am J Psychiatry 1995;152:821-825